Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment

ÇAKMUR, Raif; YILDIRIM, Ayşe Elif; ALTINAYAR, SİBEL

Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment

Ayşe Elif YILDIRIM, (Işık Üniversitesi, Psikoloji Bölümü, İstanbul, Türkiye)

Sibel ALTINAYAR, (İnönü Üniversitesi,Tıp Fakültesi, Nöroloji Anabilim Dalı, Malatya, Türkiye)

Raif ÇAKMUR (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, İzmir, Türkiye)

Neurological sciences and neurophysiology (Online)

1 0

Yıl: 2020 Cilt: 37 Sayı: 1 Sayfa Aralığı: 11 - 17 Metin Dili: Türkçe İndeks Tarihi: 18-06-2021

Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment

Öz:

Objective: Dopaminergic treatment is proved to ameliorate motor deficits in Parkinson’s disease (PD); however, it could have negative effects on behavior and cognition, including impulse controlling and decision‑making. We aimed (1) to investigate the decision‑making and impulse‑control disorders (ICDs) of PD patients and their correlations with sociodemographical and clinical variables, dopaminergic treatment in particular, and (2) to determine the relation of decision‑making with ICDs. Methods: The sample of 39 patients with PD and 37 healthy controls underwent cognitive tests and the task which analyzeddecision‑making (Iowa Gambling Task [IGT]). Besides assessing motor andnonmotor symptoms of patients with PD, ICDs were also scanned using theQuestionnaire for Impulsive‑Compulsive Disorders in Parkinson’s Disease.Results: Although patients with PD performed similarly to healthy controls on IGT,decision‑making profile in PD related to clinical variables: dopaminergic treatmentand duration of illness. In addition to this younger age of onset, higher dose ofdopamine agonists, longer duration of illness, and impaired decision‑making weretogether accounted for a substantial amount of variance in impulsive behaviors.Conclusions: Dopaminergic medication likely contributes to the impairmentin decision‑making, which may be the underlying mechanism of ICDs. Furtherstudies will be necessary to understand the potential implications of this finding.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver‑Dunckley ED, et al. Validation of the questionnaire for impulsive‑compulsive disorders in Parkinson’s disease. Mov Disord 2009;24:1461‑7.
2. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969‑73.
3. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570‑4.
4. Gallagher DA, O’Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson’s disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757‑63.
5. Rossi M, Gerschcovich ER, de Achaval D, Perez‑Lloret S, Cerquetti D, Cammarota A, et al. Decision‑making in Parkinson’s disease patients with and without pathological gambling. Eur J Neurol 2010;17:97‑102.
6. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, et al. Mechanisms underlying dopamine‑mediated reward bias in compulsive behaviors. Neuron 2010;65:135‑42.
7. Evens R, Hoefler M, Biber K, Lueken U. The Iowa Gambling Task in Parkinson’s disease: A meta‑analysis on effects of disease and medication. Neuropsychologia 2016;91:163‑72.
8. Cools R, Barker RA, Sahakian BJ, Robbins TW. L‑Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 2003;41:1431‑41.
9. Poletti M, Frosini D, Lucetti C, Del Dotto P, Ceravolo R, Bonuccelli U. Decision making in de novo Parkinson’s disease. Mov Disord 2010;25:1432‑6.
10. Kobayakawa M, Koyama S, Mimura M, Kawamura M. Decision making in Parkinson’s disease: Analysis of behavioral and physiological patterns in the Iowa Gambling Task. Mov Disord 2008;23:547‑52.
11. Frank MJ, Seeberger LC, O’reilly RC. By carrot or by stick: Cognitive reinforcement learning in Parkinsonism. Science 2004;306:1940‑3.
12. Claassen DO, van den Wildenberg WPM, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci 2011;125:492‑500.
13. Folstein MF, Folstein SE, McHugh PR. “Mini‑mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189‑98.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56‑62.
15. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non‑motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol 2006;5:235‑45.
16. Benton AL. Differential behavioural effects in frontal lobe disease. Neuropsychologia 1968;6:53‑60.
17. Oktem O. A verbal test of memory processes: A preliminary study. Arch Neuropsychiatry 1992;29:196‑206. 18. Reitan RM, Wolfson D. The Halstead‑Reitan Neuropsychological Test Battery. Tucson: Neuropsychology Press; 1985.
19. Bechara A, Damasio H, Tranel D, Anderson SW. Dissociation of working memory from decision making within the human prefrontal cortex. J Neurosci 1998;18:428‑37.
20. Euteneuer F, Schaefer F, Stuermer R, Boucsein W, Timmermann L, Barbe MT, et al. Dissociation of decision‑making under ambiguity and decision‑making under risk in patients with Parkinson’s disease: A neuropsychological and psychophysiological study. Neuropsychologia 2009;47:2882‑90.
21. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson’s disease: Influence of dopatherapy. Neuropsychologia 2002;40:2257‑67.
22. Mimura M, Oeda R, Kawamura M. Impaired decision‑making in Parkinson’s disease. Parkinsonism Relat Disord 2006;12:169‑75.
23. Ibarretxe‑Bilbao N, Junque C, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, et al. Neuroanatomical correlates of impaired decision‑making and facial emotion recognition in early Parkinson’s disease. Eur J Neurosci 2009;30:1162‑71.
24. Boller JK, Barbe MT, Pauls KA, Reck C, Brand M, Maier F, et al. Decision‑making under risk is improved by both dopaminergic medication and subthalamic stimulation in Parkinson’s disease. Exp Neurol 2014;254:70‑7.
25. Sharp ME, Foerde K, Daw ND, Shohamy D. Dopamine selectively remediates ‘model‑based’ reward learning: A computational approach. Brain 2016;139:355‑64.
26. Poletti M, Cavedini P, Bonuccelli U. Iowa Gambling Task in Parkinson’s disease. J Clin Exp Neuropsychol 2011;33:395‑409.
27. Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, et al. Dopamine agonists and risk: Impulse control disorders in Parkinson’s disease. Brain 2011;134:1438‑46.
28. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in Parkinson’s disease? Neuropsychopharmacology 2009;34:2758‑66.
29. Kobayakawa M, Tsuruya N, Kawamura M. Decision‑making performance in Parkinson’s disease correlates with lateral orbitofrontal volume. J Neurol Sci 2017;372:232‑8.
30. Merola A, Romagnolo A, Rizzi L, Rizzone MG, Zibetti M, Lanotte M, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol 2017;264:40‑8.
31. Al‑Khaled M, Heldmann M, Bolstorff I, Hagenah J, Münte TF. Intertemporal choice in Parkinson’s disease and restless legs syndrome. Parkinsonism Relat Disord 2015;21:1330‑5.
32. Robert G, Drapier D, Verin M, Millet B, Azulay JP, Blin O. Cognitive impulsivity in Parkinson’s disease patients: Assessment and pathophysiology. Mov Disord 2009;24:2316‑27.
33. Rao H, Korczykowski M, Pluta J, Hoang A, Detre JA. Neural correlates of voluntary and involuntary risk taking in the human brain: An fMRI Study of the Balloon Analog Risk Task (BART). Neuroimage 2008;42:902‑10.
34. Antonelli F, Ko JH, Miyasaki J, Lang AE, Houle S, Valzania F, et al. Dopamine‑agonists and impulsivity in Parkinson’s disease: Impulsive choices vs. impulsive actions. Hum Brain Mapp 2014;35:2499‑506.
35. Goerendt IK, Lawrence AD, Brooks DJ. Reward processing in health and Parkinson’s disease: Neural organization and reorganization. Cereb Cortex 2004;14:73‑80.
36. MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA. Parkinson’s disease duration determines effect of dopaminergic therapy on ventral striatum function. Mov Disord 2013;28:153‑60.
37. Brand M, Labudda K, Markowitsch HJ. Neuropsychological correlates of decision‑making in ambiguous and risky situations. Neural Netw 2006;19:1266‑76.
38. Castrioto A, Funkiewiez A, Debû B, Cools R, Lhommée E, Ardouin C, et al. Iowa Gambling Task impairment in Parkinson’s disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry 2015;86:186‑90.

APA	YILDIRIM A, ALTINAYAR S, ÇAKMUR R (2020). Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. , 11 - 17.
Chicago	YILDIRIM Ayşe Elif,ALTINAYAR SİBEL,ÇAKMUR Raif Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. (2020): 11 - 17.
MLA	YILDIRIM Ayşe Elif,ALTINAYAR SİBEL,ÇAKMUR Raif Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. , 2020, ss.11 - 17.
AMA	YILDIRIM A,ALTINAYAR S,ÇAKMUR R Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. . 2020; 11 - 17.
Vancouver	YILDIRIM A,ALTINAYAR S,ÇAKMUR R Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. . 2020; 11 - 17.
IEEE	YILDIRIM A,ALTINAYAR S,ÇAKMUR R "Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment." , ss.11 - 17, 2020.
ISNAD	YILDIRIM, Ayşe Elif vd. "Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment". (2020), 11-17.

APA	YILDIRIM A, ALTINAYAR S, ÇAKMUR R (2020). Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. Neurological sciences and neurophysiology (Online), 37(1), 11 - 17.
Chicago	YILDIRIM Ayşe Elif,ALTINAYAR SİBEL,ÇAKMUR Raif Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. Neurological sciences and neurophysiology (Online) 37, no.1 (2020): 11 - 17.
MLA	YILDIRIM Ayşe Elif,ALTINAYAR SİBEL,ÇAKMUR Raif Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. Neurological sciences and neurophysiology (Online), vol.37, no.1, 2020, ss.11 - 17.
AMA	YILDIRIM A,ALTINAYAR S,ÇAKMUR R Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. Neurological sciences and neurophysiology (Online). 2020; 37(1): 11 - 17.
Vancouver	YILDIRIM A,ALTINAYAR S,ÇAKMUR R Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment. Neurological sciences and neurophysiology (Online). 2020; 37(1): 11 - 17.
IEEE	YILDIRIM A,ALTINAYAR S,ÇAKMUR R "Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment." Neurological sciences and neurophysiology (Online), 37, ss.11 - 17, 2020.
ISNAD	YILDIRIM, Ayşe Elif vd. "Decision‑Making and Impulse‑Control Disorders in Parkinson’s Disease: Influence of Dopaminergic Treatment". Neurological sciences and neurophysiology (Online) 37/1 (2020), 11-17.